1. Introduction {#sec1-ijms-20-00605}
===============

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide because more than half a million people are diagnosed with this malignancy yearly \[[@B1-ijms-20-00605]\]. HCC generally develops in patients with liver cirrhosis due to persistent hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, alcohol consumption, and immune-related hepatitis \[[@B2-ijms-20-00605]\]. Active surveillance and watchful observation are used to diagnose HCC at an early stage in these high-risk patients. However, the prognosis of patients with this malignancy is very poor because only 46% of patients with HCC are diagnosed at an early stage, and most do not receive curative therapy \[[@B3-ijms-20-00605],[@B4-ijms-20-00605]\]. Furthermore, even patients with HCC in whom curative therapy can be performed are extremely prone to recurrence; in fact, the 5-year recurrence rate after curative treatment has been reported to be more than 70% \[[@B5-ijms-20-00605],[@B6-ijms-20-00605]\]. Therefore, in order to reduce the mortality of HCC, it is very important to identify significant predictors of HCC development and recurrence, as these factors are useful in the surveillance strategy.

In addition to the established risk factors such as HBV, HCV, and alcohol consumption, several components of the metabolic syndrome have been reported to be involved in the increased risk of HCC \[[@B7-ijms-20-00605]\]. We have previously demonstrated that increases in the serum levels of leptin and oxidative stress and increased visceral fat accumulation, all of which are involved in obesity, predict the recurrence of HCC after curative treatment \[[@B8-ijms-20-00605],[@B9-ijms-20-00605],[@B10-ijms-20-00605]\]. Among lifestyle-related diseases, diabetes mellitus (DM) is most deeply involved in liver carcinogenesis \[[@B7-ijms-20-00605],[@B11-ijms-20-00605],[@B12-ijms-20-00605],[@B13-ijms-20-00605]\]. Obesity-related and diabetes-related metabolic disorders, such as impaired insulin sensitivity and non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), contribute to increasing the incidence of HCC with a non-viral etiology \[[@B14-ijms-20-00605]\]. Importantly, a higher level of homeostasis model assessment-insulin resistance (HOMA-IR), an indicator of insulin resistance, is associated with an increased risk for recurrence of stage I HCC after curative treatment in HCV-positive patients \[[@B15-ijms-20-00605]\]. These findings suggest that several indicators that are associated with metabolic syndrome, in particular, glucose metabolism abnormality, may be useful in assessing the recurrence risk for HCC after curative treatment.

In this study, we examined the impact of the complication of DM and the factors associated with glucose metabolism, including hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), fasting immunoreactive insulin (FIRI), and HOMA-IR, on the recurrence of HCC in patients who received curative treatment for this malignancy. The purpose of this study was to determine whether these indicators can predict HCC recurrence after initial curative treatment.

2. Results {#sec2-ijms-20-00605}
==========

2.1. Baseline Characteristics and Laboratory Data {#sec2dot1-ijms-20-00605}
-------------------------------------------------

The baseline characteristics and laboratory data of the 211 patients (148 men and 63 women, average age 70.6 years) and the comparison of the groups with (*n* = 71) and without DM (*n* = 140) are shown in [Table 1](#ijms-20-00605-t001){ref-type="table"}. These data were collected immediately before initial treatment. All the diabetic patients in this study were classified as having type 2 DM. HBV-negative and HCV-negative HCC was observed more often in patients with DM than in those without DM (*p* \< 0.001), and patients with DM had a significantly higher body mass index (*p* \< 0.001), HbA1c level (*p* \< 0.001), FPG level (*p* \< 0.001), HOMA-IR level (*p* = 0.047), and serum triglyceride level (*p* = 0.003). Serum total bilirubin levels were significantly lower (*p* = 0.022) but serum albumin levels were significantly higher (*p* = 0.028) in patients with DM than in those without DM. In addition, the frequencies of hypertension (*p* \< 0.001), hyperlipidemia (*p* = 0.007), and NAFLD/NASH (*p* \< 0.001) were significantly higher in patients with DM than in those without DM. There were no significant differences in age, serum levels of alanine aminotransferase, the platelet count, Child--Pugh score, first treatment regimen, and tumor-related factors, such as tumor makers (AFP and PIVKA-II) and clinical cancer stage, between the groups with and without DM.

2.2. Impact of DM (Diabetes Mellitus) and Glucose Metabolism-Related Factors on Recurrence-Free Survival in Patients with HCC (Hepatocellular Carcinoma) after Curative Treatmen {#sec2dot2-ijms-20-00605}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The 1-year, 3-year, and 5-year recurrence-free survival rates of all enrolled patients were 63.0, 32.9, and 20.5%, respectively. As shown in [Figure 1](#ijms-20-00605-f001){ref-type="fig"}, there was no significant difference in the recurrence-free survival rate between the patients with and without DM (*p* = 0.144). There were also no significant differences between higher and lower levels of HbA1c (≥6.5 and \<6.5%, respectively; *p* = 0.509; [Figure 2](#ijms-20-00605-f002){ref-type="fig"}a), FPG (≥126 and \<126 mg/dL, respectively; *p* = 0.143; [Figure 2](#ijms-20-00605-f002){ref-type="fig"}b), and FIRI (≥10 and \<10 μU/mL, respectively; *p* = 0.248; [Figure 2](#ijms-20-00605-f002){ref-type="fig"}c). However, the higher HOMA-IR group (≥2.3) had HCC recurrence significantly earlier than the lower HOMA-IR group (\<2.3, *p* = 0.013; [Figure 2](#ijms-20-00605-f002){ref-type="fig"}d). Moreover, there was a significant difference between the higher and lower HOMA-IR groups when the patients did not have DM (*p* = 0.009; [Figure 3](#ijms-20-00605-f003){ref-type="fig"}a), as there was no significant difference when the patients had DM (*p* = 0.759; [Figure 3](#ijms-20-00605-f003){ref-type="fig"}b). Similar results were also obtained from the subanalysis of the 195 patients without NASH/NAFLD, which is highly prevalent in type 2 DM \[[@B11-ijms-20-00605]\]. Specifically, the factors associated with a glucose metabolism disorders, such as DM (*p* = 0.092; [Supplementary Figure S1](#app1-ijms-20-00605){ref-type="app"}), higher HbA1c level (*p* = 0.179; [Supplementary Figure S2a](#app1-ijms-20-00605){ref-type="app"}), FPG level (*p* = 0.115; [Supplementary Figure S2b](#app1-ijms-20-00605){ref-type="app"}), and FIRI level (*p* = 0.284; [Supplementary Figure S2c](#app1-ijms-20-00605){ref-type="app"}), were not significant predictors of HCC recurrence; only higher HOMA-IR level predicted recurrence (*p* = 0.015; [Supplementary Figure S2d](#app1-ijms-20-00605){ref-type="app"}). Moreover, even in non-NASH/NAFLD patients without DM, higher HOMA-IR level had a significant impact on HCC recurrence (*p* = 0.011; [Supplementary Figure S3a](#app1-ijms-20-00605){ref-type="app"}), whereas there was no significant difference in patients with DM (*p* = 0.686; [Supplementary Figure S3b](#app1-ijms-20-00605){ref-type="app"}).

[Table 2](#ijms-20-00605-t002){ref-type="table"} summarizes the predictors of HCC recurrence. Univariate analysis revealed that higher body mass index (*p* = 0.049) and HOMA-IR level (*p* = 0.014) were significant risk factors of HCC recurrence. Multivariate analysis identified that higher HOMA-IR level is the only independent predictor of HCC recurrence in this study (hazard ratio, 1.485; 95% confidence interval, 1.030--2.139; *p* = 0.034). This finding was consistent with that of a previous report demonstrating that higher HOMA-IR level is an independent predictor of stage-I HCC recurrence after curative radiofrequency ablation treatment in HCV-positive patients \[[@B15-ijms-20-00605]\].

3. Discussion {#sec3-ijms-20-00605}
=============

It is widely accepted that there is a strong relationship between DM and the development of HCC \[[@B7-ijms-20-00605],[@B11-ijms-20-00605],[@B12-ijms-20-00605],[@B13-ijms-20-00605],[@B16-ijms-20-00605]\]. A meta-analysis revealed that DM is associated with an approximately 2.5-fold increased risk of HCC \[[@B7-ijms-20-00605]\]. The presence of DM remained an independent risk factor of HCC after adjusting for alcohol consumption or viral hepatitis \[[@B7-ijms-20-00605],[@B13-ijms-20-00605],[@B17-ijms-20-00605]\]. Several studies have also described synergistic interactions between DM and other HCC risk factors, such as viral hepatitis infection and alcohol consumption \[[@B12-ijms-20-00605],[@B18-ijms-20-00605],[@B19-ijms-20-00605]\]. In addition, DM is closely linked to NASH that is involved in the development of HCC \[[@B11-ijms-20-00605]\]. Endogenous and/or exogenous hyperinsulinemia, hyperglycemia, and chronic inflammation observed in diabetic patients may be involved in liver carcinogenesis \[[@B12-ijms-20-00605]\]. In particular, insulin resistance and hyperinsulinemia play a critical role in the development of HCC because insulin can exert a potentially mitogenic effect by activating its receptor in both precancerous and cancer cells \[[@B20-ijms-20-00605]\].

The results of the present study clearly demonstrated that a higher HOMA-IR level (≥2.3), which is commonly used for evaluating insulin resistance \[[@B21-ijms-20-00605],[@B22-ijms-20-00605]\], can be used to predict the early recurrence of HCC, whereas the complication of DM, a higher HbA1c level (≥6.5), higher FPG level (≥126), and higher FIRI level (≥10) were not associated with recurrence. Moreover, non-diabetic patients with a higher HOMA-IR level had a significantly increased risk of HCC recurrence after curative treatment, but diabetic patients with a higher HOMA-IR did not. These findings suggest that insulin resistance may be critically involved in the recurrence of HCC, and that a higher HOMA-IR level is an effective and useful predictor of recurrence. However, we should pay careful attention to the accuracy of HOMA-IR, as it might be decreased in advanced diabetic patients because hyperglycemia induces the inadequate secretion of insulin and the homeostasis between fasting glucose and insulin levels is disrupted in these patients \[[@B21-ijms-20-00605]\]. Therefore, HOMA-IR should be used as a predictor of HCC recurrence, especially when the patients have a slight glucose tolerance disorder or are in a pre-diabetic phase.

In this study, the complication of DM did not promote the recurrence of HCC. These findings may indicate that diabetic patients are not necessarily apt to have an increased risk of the development and recurrence of HCC when they undergo adequate DM treatment. Improvement of both hyperinsulinemia and hyperglycemia and other metabolic abnormalities associated with obesity might be an effective strategy for preventing the development of HCC in patients with metabolic syndrome \[[@B23-ijms-20-00605],[@B24-ijms-20-00605],[@B25-ijms-20-00605]\]. Exercise and nutritional therapies are essential for improving hyperinsulinemia, insulin resistance, hyperglycemia, and obesity in patients with DM \[[@B26-ijms-20-00605],[@B27-ijms-20-00605]\]. Moreover, some studies have suggested that antidiabetic drugs affect the development of HCC \[[@B12-ijms-20-00605]\]. For instance, metformin lowers the incidence of cancers, including HCC, in patients with DM \[[@B28-ijms-20-00605],[@B29-ijms-20-00605]\]. Thiazolidinediones, which lower insulin resistance without directly affecting insulin secretion, also significantly decreased the risk of liver cancer \[[@B30-ijms-20-00605]\]. On the other hand, insulin secretagogues and insulin analogs may increase the risk of HCC in diabetic patients \[[@B31-ijms-20-00605],[@B32-ijms-20-00605],[@B33-ijms-20-00605],[@B34-ijms-20-00605]\]. These reports, together with the present study's results, may suggest that improvement of a lifestyle habit, such as exercise and nutrition, and usage of antidiabetic drugs, which lower insulin resistance, are effective ways to prevent the development and recurrence of HCC in diabetic patients.

This study has several limitations. First, it was a retrospective, single-center study and the sample size of HCC patients with DM was comparatively small. Second, it remains unclear whether adequate DM treatment, which improves both hyperglycemia and hyperinsulinemia, could reduce the risk of HCC recurrence in patients with DM because glucose metabolism was evaluated only once, immediately before initial treatment. These limitations might cause a bias or influence the results of this study. Therefore, long-term, prospective studies in a larger number of patients should be performed to confirm the findings and the possibilities obtained from the present study. Moreover, the possibility that hyperglycemia, in addition to insulin resistance, which was revealed in the present study, is involved in HCC recurrence cannot be denied. Hyperglycemia among diabetic patients can increase oxidative stress in the cells, which can induce cancer development \[[@B22-ijms-20-00605],[@B23-ijms-20-00605]\]. Improvement of hyperinsulinemia and hyperglycemia as well as obesity-related metabolic abnormalities might be beneficial in suppressing the development and/or the recurrence of HCC regardless of DM.

It should be emphasized again that a rapid and abundant increase in the incidence of HCC with a non-viral etiology is a serious health care problem worldwide \[[@B35-ijms-20-00605]\]. Obesity-related and diabetes-related metabolic disorders have a great impact on such liver carcinogenesis and, therefore, can be beneficial markers for identifying the high-risk patients with HCC.

4. Materials and Methods {#sec4-ijms-20-00605}
========================

4.1. Patients, Treatment, and Determination of Recurrence {#sec4dot1-ijms-20-00605}
---------------------------------------------------------

The diagnosis of HCC was made from a typical dynamic-study finding of enhanced staining in the early phase and attenuation in the delayed phase using imaging modalities including enhanced ultrasonography, dynamic computed tomography (CT), and dynamic magnetic resonance imaging (MRI). The selection criteria for the initial treatments were determined according to the guidelines for HCC by the Liver Cancer Study Group of Japan \[[@B36-ijms-20-00605]\]. Patients were thereafter followed up with on an outpatient basis to assess the levels of serum tumor markers such as alpha-fetoprotein (AFP) and proteins induced by vitamin K absence or antagonist-II (PIVKA-II), and imaging modalities such as dynamic CT and MRI were performed every 3 months. Recurrent HCC was defined as the imaging characteristics of HCC described above of distant lesions in order to exclude local recurrence. The recurrence-free survival time was defined as the interval from the date of the initial treatment to the date of the recurrence or December 2017 for recurrence-free survivors.

We diagnosed 415 patients as having primary HCC in our hospital from 2006 to 2017. Among them, we determined that 211 patients were curative and enrolled them in this study, and they all met the following criteria: surgical resection or radiofrequency ablation conducted for the initial HCC treatment; and the imaging modalities after initial treatment exhibited complete disappearance of the imaging characteristics of HCC described above.

All study participants provided verbal informed consent, which was considered sufficient, as this study followed an observational research design that did not require new human specimens. This study design, including this consent procedure, was approved by the ethics committee of the Gifu University School of Medicine (approval number 29-26).

4.2. Examination of Glucose Metabolism {#sec4dot2-ijms-20-00605}
--------------------------------------

In order to evaluate glucose metabolism, the levels of HbA1c, FPG, FIRI, and HOMA-IR were measured before curative treatment of HCC. We determined patients as having DM if they already underwent DM treatment or met the following criteria: HbA1c level ≥6.5%, FPG level ≥126 mg/dL, or random plasma glucose level ≥200 mg/dL \[[@B37-ijms-20-00605]\]. HOMA-IR was calculated as follows: HOMA-IR = FIRI × FPG/405 \[[@B22-ijms-20-00605]\]. We set the cut-off values for HbA1c, FPG, and FIRI at 6.5%, 126 mg/dL, and 10 μU/mL, respectively, based on the generally established standard values \[[@B37-ijms-20-00605]\]. The cut-off value for HOMA-IR was set at 2.3, which predicted the recurrence of stage I HCC after curative treatment in a previous study \[[@B15-ijms-20-00605]\].

4.3. Statistical Analysis {#sec4dot3-ijms-20-00605}
-------------------------

Baseline characteristics were compared using Student's *t*-test for continuous variables or the χ^2^ test for categorical variables. Holm-Bonferroni correction was used to counteract the problem of multiple comparisons \[[@B38-ijms-20-00605]\]. Univariate and multivariate analyses were performed using the Cox proportional hazards model to identify the risk factors of HCC recurrence. Recurrence-free survival was estimated using the Kaplan--Meier method, and differences between curves were evaluated using the log-rank test. Statistical significance was defined as *P* \< 0.05. All statistical analyses were performed using R version 3.3.3 (The R Project for Statistical Computing, Vienna, Austria; <http://www.R-project.org/>).

5. Conclusions {#sec5-ijms-20-00605}
==============

A higher HOMA-IR level, an insulin resistance marker, is associated with HCC recurrence after curative treatment. In particular, HOMA-IR in non-diabetic patients is an extremely useful tool for predicting the recurrence risk of HCC. In order to identify the recurrence of HCC in the early stage, active surveillance is especially needed for these patients.

Supplementary materials can be found at <http://www.mdpi.com/1422-0067/20/3/605/s1>.
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![Kaplan--Meier curves for recurrence-free survival time in patients with and without diabetes mellitus.](ijms-20-00605-g001){#ijms-20-00605-f001}

![Kaplan--Meier curves for recurrence-free survival time divided into higher and lower (≥6.5 and \<6.5%, respectively) hemoglobin A1c (HbA1c) groups (**a**), higher and lower (≥126 and \<126 mg/dL, respectively) fasting plasma glucose (FPG) groups (**b**), higher and lower (≥10 and \<10 μU/mL, respectively) fasting immunoreactive insulin (FIRI) groups (**c**), and higher and lower (≥2.3 and \<2.3, respectively) homeostasis model assessment-insulin resistance (HOMA-IR) groups (**d**).](ijms-20-00605-g002){#ijms-20-00605-f002}

![Kaplan--Meier curves for recurrence-free survival time divided into higher and lower (≥2.3 and \<2.3, respectively) homeostasis model assessment-insulin resistance (HOMA-IR) groups without (**a**) or with diabetes mellitus (DM) (**b**).](ijms-20-00605-g003){#ijms-20-00605-f003}

ijms-20-00605-t001_Table 1

###### 

Baseline demographic and clinical characteristics of patients with and without diabetes mellitus.

  ----------------------------------------------------------------------------------------------------
                                      All Cases\        DM (−)\          DM (+)\           *p*-Value
                                      (*n* = 211)       (*n* = 140)      (*n* = 71)        
  ----------------------------------- ----------------- ---------------- ----------------- -----------
  Sex (male/female)                   148/63            96/44            52/19             0.527

  Age (years)                         70.6 ± 9.1        71.0 ± 8.9       69.8 ± 9.4        0.377

  Etiology (HBV/HCV/others)           28/131/52         21/97/22         7/34/30           \<0.001

  BMI (kg/m^2^)                       23.1 ± 3.1        22.5 ± 2.8       24.3 ± 3.4        \<0.001

  Child-Pugh score (5/6/7/8/9/10)     137/44/18/8/2/2   87/29/14/7/1/2   50/15/4/1/10      0.547

  ALB (g/dL)                          3.8 ± 0.5         3.7 ± 0.5        3.9 ± 0.5         0.028

  ALT (IU/L)                          40.4 ± 29.9       39.5 ± 24.1      42.0 ± 39.1       0.577

  T-Bil (mg/dL)                       1.0 ± 0.6         1.1 ± 0.6        0.9 ± 0.4         0.022

  PLT (×10^4^/μL)                     13.2 ± 6.3        12.8 ± 6.0       14.1 ± 17.1       0.131

  PT (%)                              87.1 ± 16.3       86.3 ± 15.5      88.6 ± 18.0       0.338

  FPG (mg/dL)                         112.2 ± 34.7      100.4 ± 15.8     135.5 ± 47.8      \<0.001

  FIRI (μU/mL)                        12.1 ± 16.1       11\. 2 ± 9.7     14.0 ± 24.2       0.243

  HbA1c (%)                           6.1 ± 1.2         5.6 ± 0.7        7.0 ± 1.4         \<0.001

  HOMA-IR                             3.5 ± 6.5         2.9 ± 3.0        4.8 ± 10.3        0.047

  TG (mg/dL)                          102.6 ± 58.0      93.6 ± 40.4      120.2 ± 79.6      0.003

  AFP (ng/dL)                         552 ± 2440        626 ± 2376       409 ± 2573        0.542

  PIVKA-II (mAU/mL)                   6440 ± 46 580     2482 ± 17 335    14 244 ± 76 284   0.085

  Stage (I/II/III/IV)                 76/93/38/4        52/59/26/3       24/34/12/1        0.911

  Initial treatment (resection/RFA)   99/112            63/77            36/35             0.523

  Co-existing diseases (yes/no)                                                            

  Renal disease                       11/200            6/134            5/66              0.513

  Heart disease                       27/184            14/126           13/58             0.125

  Neurologic disease                  12/199            6/134            6/65              0.224

  Hypertension                        86/125            42/98            44/27             \<0.001

  Hyperlipidemia                      17/194            6/134            11/60             0.007

  NAFLD/NASH                          16/195            3/137            13/58             \<0.001
  ----------------------------------------------------------------------------------------------------

Values are presented as a mean ± standard deviation. DM, diabetes mellitus; HBV, hepatitis B virus; HCV, hepatitis C virus; BMI, body mass index; ALT, alanine aminotransferase; T-Bil, total bilirubin; PLT, platelet count; PT, prothrombin time; FPG, fasting plasma glucose; FIRI, fasting immunoreactive insulin; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model assessment-insulin resistance; TG, triglyceride; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonists-II; RFA, radiofrequency ablation; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.

ijms-20-00605-t002_Table 2

###### 

Univariate and multivariate analyses to predict hepatocellular carcinoma recurrence in all patients.

  --------------------------------------------------------------------------------------------------------
                             Univariate Analysis    Multivariate Analysis                          
  -------------------------- ---------------------- ----------------------- ---------------------- -------
  Sex (male vs. female)      1.221 (0.829--1.798)   0.311                                          

  Age (years)                0.993 (0.973--1.014)   0.525                                          

  BMI (kg/m^2^)              1.061 (1.000--1.125)   0.049                   1.047 (0.986--1.111)   0.134

  Child (A vs. B/C)          1.032 (0.609--1.746)   0.908                                          

  Albumin (g/dL)             0.939 (0.647--1.361)   0.738                                          

  PLT (×10^4^/mL)            0.988 (0.959--1.018)   0.434                                          

  HOMA-IR (≥2.3 vs. \<2.3)   1.565 (1.095--2.239)   0.014                   1.485 (1.030--2.139)   0.034

  AFP (ng/dL)                1.000 (0.999--1.000)   0.503                                          

  PIVKA-II (mAU/mL)          1.000 (1.000--1.000)   0.168                                          

  Stage (I vs. II/III/IV)    0.913 (0.632--1.320)   0.628                                          

  Initial treatment\         1.103 (0.771-1.577)    0.592                                          
  (RFA vs. resection)                                                                              
  --------------------------------------------------------------------------------------------------------

HR, hazard ratio; CI, confidence interval; BMI, body mass index; PLT, platelet count; HOMA-IR, homeostasis model assessment-insulin resistance; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonists-II; RFA, radiofrequency ablation.
